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ABSTRACT 
   
The majority of non-small cell lung cancer (NSCLC) patients (70%) are diagnosed with 
adenocarcinoma versus other histological subtypes. These patients often present with advanced, 
metastatic disease and frequently relapse after treatment.  The tumor suppressor, Liver Kinase 
B1, is frequently inactivated in adenocarcinomas and loss of function is associated with a highly 
aggressive, metastatic tumor (1). Identification of the mechanisms deregulated with LKB1 
inactivation could yield targeted therapeutic options for adenocarcinoma patients. Re-purposing 
the immune system to support tumor growth and aid in metastasis has been shown to be a 
feature in cancer progression (2). Tumor associated macrophages (TAMs) differentiate from 
monocytes, which are recruited to the tumor microenvironment via secretion of chemotaxic 
factors by cancer cells. We find that NSCLC cells deficient in LKB1 display increased secretion of 
C-C motif ligand 2 (CCL2), a chemokine involved in monocyte recruitment. To elucidate the 
molecular pathway regulating CCL2 up-regulation, we investigated inhibitors of substrates 
downstream of LKB1 signaling in A549, H23, H2030 and H838 cell lines. Noticeably, BAY-11-
7082 (NF-κB inhibitor) reduced CCL2 secretion by an average 92%. We further demonstrate that 
a CCR2 antagonist and neutralizing CCL2 antibody substantially reduce monocyte migration to 
NSCLC (H23) cell line conditioned media. Using an in vivo model of NSCLC, we find that LKB1 
deleted tumors demonstrate a discernible increase in CCL2 levels compared to normal lung. 
Moreover, tumors display an increase in the M2:M1 macrophage ratio and increase in tumor 
associated neutrophil (TAN) infiltrate compared to normal lung. This M2 shift was significantly 
reduced in mice treated with anti-CCL2 or a CCR2 antagonist and the TAN infiltrate was 
significantly reduced with the CCR2 antagonist. These data suggest that deregulation of the 
CCL2/CCR2 signaling axis could play a role in cancer progression in LKB1 deficient tumors. 
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CHAPTER 1 
INTRODUCTION 
LUNG CANCER 
Lung cancer accounts for up to 27% of all cancer related deaths and despite aggressive 
chemotherapeutic treatments, there has been little improvement in patient survival (3). Lung 
cancer consists of two broad classes: Non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC). 85% of lung cancers are NSCLC, which can be subdivided into histologically 
distinct types: adenocarcinoma (glandular), squamous (inner lining of the bronchial tubes) and 
large cell carcinoma. 70% of NSCLC are adenocarcinomas and although there have been 
advances in targeted therapeutics for Epithelial Growth Factor Receptor (EGFR) and EML4-ALK 
mutations, those mutations represent a low frequency in adenocarcinoma populations (3). The 
tumor suppressor Liver Kinase B1 (LKB1) is the second most mutated gene (behind TP53) in 
NSCLC (4). Loss of LKB1 in conjunction with oncogenic activation of KRas promotes aggressive, 
metastatic tumors in transgenic models (1). Notably, inactivation of LKB1 is commonly present in 
the background of oncogenic KRas mutations in patients. This cancer subtype represents a 
genetically unique tumor population (5). The standard care for these patients is chemo-radiation 
therapy, which results in little improvement in survival (6). Due to the high incidence of metastatic 
disease in NSCLC patients, effective treatment options are a significant challenge, indicating a 
considerable need for specific therapeutics in LKB1/KRas cancers. 
LKB1 was initially recognized for its role in a heritable cancer disorder, Peutz-Jeghers syndrome, 
but has been recently acknowledged to be mutated in other spontaneous cancers, including 30% 
of NSCLC (7). LKB1 phosphorylates AMP-activated protein kinase (AMPK), a major sensor of 
cellular energetic stress. The LKB1-AMPK pathway is active under energetic stress or hypoxic 
conditions, causing cellular arrest to ensure survival (7). AMPK also regulates metabolism by 
stimulating glucose uptake and inhibiting protein synthesis, leading to energy conservation at the 
expense of cell growth and proliferation. Although AMPK is mostly known for its effects on cell 
metabolism, it also regulates mitochondrial biogenesis and disposal, autophagy and cell polarity. 
Loss of LKB1- AMPK function allows tumors to escape the pathway’s restraining effects on cell 
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growth and proliferation. By targeting downstream effectors of LKB1-AMPK that are deregulated 
in LKB1 null cancers, further therapeutic options can be identified. Furthermore, the broad 
regulatory functions of LKB1 suggest that additional avenues could be utilized. LKB1 also has 
other targets in addition to AMPK such as MARK, SIK, and SAD that play an essential role in cell 
polarity. Loss of LKB1 has been shown to de-regulate these substrates and play a role in 
tumorigenesis (7). 
IMMUNE SYSTEM AND CANCER 
The integration of immunology in the study of cancer progression is becoming a critical 
connection, as the immune system has a significant role in the development of a tumor. Whether 
tumors evade recognition by the adaptive immune system, or utilize innate cell function to the 
advantage of the tumor, it is important to incorporate the influence the immune system has on 
cancer progression. 
TUMOR ASSOCIATED MACROPHAGES 
Macrophages are a type of white blood cell that primarily phagocytoses cellular debris, foreign 
substances and microbes. Monocytes, the pre-cursor to macrophages, circulate the body and are 
recruited to tissue based on the chemical gradients of a wide variety of chemokines and 
cytokines. Monocytes can polarize to classical M1 macrophages in response to Interfeuron 
gamma (IFNγ), microbial stimuli, such as Lipopolysaccharides, or cytokines such Tumor Necrosis 
Factor alpha (TNF-α) and Colony Stimulating Factor 2 (CSF-2) (8). M1 macrophages play a role 
in clearance of microbes as well as mediating resistance to intracellular parasites (9). Monocytes 
can also differentiate into alternative M2 macrophages by Transforming Growth Factor Beta 
(TGFβ) and cytokines such as Interleukin 4 or 10 (IL-4 ,IL-10). M2 macrophages play a role in 
wound healing by reducing the inflammation, remodeling tissue, promoting angiogenesis and 
stimulating cell proliferation (10). 
Tumor associated macrophages (TAMs) generally exhibit an M2 phenotype and are thought to be 
particularly important in tumorigenesis, tumor growth and metastasis. Monocytes can migrate to 
the tumor environment in response to cytokines such as CCL2, CCL5, CCL20 and then 
differentiate into TAMs in response to factors such as TGFβ and IL-10.  TAMs then secrete pro-
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tumor factors important in tumor growth and metastasis, such as Vascular Endothelial Growth 
Factor (VEGF), Extra-Cellular Matrix (ECM) proteases, Fibroblast Growth Factor (FGF) (11). By 
programming M2 polarization, cancer cells can utilize the innate immune system to sustain tumor 
growth and proliferation, aid in metastasis and recruitment of nutrients, and evade adaptive 
immunity. However, little is understood as to the mechanisms that govern these events in tumors, 
including in NSCLC. 
TUMOR ASSOCIATED NEUTROPHILS 
Tumor associated neutrophils (TANs) are derived from granulocytic cells that are produced in the 
bone marrow. Neutrophils are short-lived phagocytes that are the first responders to inflammatory 
sites. Like macrophages, neutrophils infiltrate tissue in response to cytokines such as CCL2, 
CCL3, IL-1β and IL-6 (12). Neutrophils are primarily known for their anti-bacterial functions, 
however, TANs are a distinct population differing significantly in their functional activity (13). A 
study done by Fridlender et. al demonstrated the importance of TGFβ in TAN polarization. 
Blockade of TGFβ resulted in an increase influx of anti-tumor (N1) neutrophils and a reduction of 
pro-tumor (N2) neutrophils (14). N2 neutrophils secrete products such as reactive oxygen 
species, matrix membrane proteinases (MMPs), collagenases, and aid in translocation of the 
tumor cells through vasculature. TANs have been relatively uninvestigated until recently, but 
some studies have defined roles for TANs in regulating tumor cell proliferation, angiogenesis, and 
metastasis (15). 
HYPOTHESIS 
To investigate the effects of LKB1 loss, we ran a global gene expression array on a human 
NSCLC adenocarcinoma cell line H23 re-expressing either a non-functional (kinase dead, KD) 
LKB1 or functional LKB1.  Among the genes with altered expression, CCL2 and other 
chemokines were found to be highly expressed in the Kinase Dead LKB1 cell line versus the full 
length LKB1 cell line (Table 1). Based upon the reported role of these chemokines in the 
recruitment of pro-tumorigeneic immune cells, we hypothesized that increased expression and 
secretion of CCL2 associated with LKB1 inactivation may result in a distinct immune 
microenvironment in LKB1-deficient NSCLC tumors.  Characterization of the immune cell 
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populations associated with LKB1 inactivation could provide a mechanism towards the 
aggressive nature of LKB1- NSCLC.  
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CHAPTER 2 
METHODS 
Cell Culture 
Human lung non-small cell carcinoma cells (ATCC; H23: CRL-5800, H2030: CRL-5914, H2009: 
5911, H358:CRL-5807, H441: HTB-174, H838: CRL-5834, A549:CCL-185) were maintained in 
RPMI, 10% FBS supplemented with 5% penicillin streptomycin. Peripheral Blood Mononuclear 
cells were used fresh (ZenBio; SER-PBMC). Monocytes (CRL-9855) were maintained in Iscove's 
modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate and supplemented with 0.05 mM 2-mercaptoethanol, 0.1 mM hypoxanthine and 
0.016 mM thymidine, 90%; fetal bovine serum, 10%. 
Migration Assay/Flow Cytometry 
Conditioned media was placed in the lower chamber, 4 µM polycarbonate transwell filter was 
placed in the transwell and PBMCs were placed in the upper chamber. Cells were incubated at 
37°C for two hours. Media from the lower chamber was collected and cells were trypsinized from 
lower chamber and the bottom of the filter using 5mM EDTA/PBS. Cells were suspended in an 
antibody cocktail containing CD3, CD19, CD56, HLA-DR, CD14, CD11c (ebioscience cat# 11-
0039-42, 11-0199-42, 11-0569-42, 12-9952-42, 11-45-0149, 17-0016-42 respectively) and run 
through Accuri C6 flow cytometer. 
ELISA 
Cells were dosed with vehicle, Dasatinib 250nM, LY294002 10mM, U0126 10µM, Rapamycin 
10nM, Bortezomib 100nM or Bay-11-7082 5µM (Selleck,Cat No.S1021, S1105, S1102, S1039, 
S1013, S2913 respectively) for 24 hours. Cell culture supernatant was collected and a 
quantitative CCL2 ELISA performed (R&D cat# DCP00). Cell culture supernatant was also 
collected from H23 KD LKB1 and full-length LKB1, CMT64 and CRISPR LKB1 CMT64. 
siRNA depletion of HIF1-α 
5nM si-HIF1-α (QIAGEN, SI02664431) was diluted into Opti-MEM and HiPerFect transfection 
reagent added (QIAGEN, 301702) in H23 and H2030 cell lines. Cell lysates and media were 
collected after 24 hours. 
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CRISPR mediated deletion of LKB1 
6µg of Lenti Viral plasmid (U6-gRNA/EFa-puro-2A-Cas92Z-GFP) is mixed with Lipofectamine 
2000 and Lentiviral Packaging Mix (Sigma, SHP001) and added dropwise to 293T cells. Media is 
changed after 24 hours, then collected at 72 hours. Viral media is filtered through a .45µM 
strainer onto H2009 and CMT64 cells. Transdux at 1:1000 is added (Systems Bio, LV850A-1). 
Cells are selected with 3µg/ml of puromycin 48 hours post infection.  
NF-kB p50/p65 Transcription Factor Assay Kit  
Nuclear and Cytoplasmic lysates were collected from H23 and H2030 cell lines. The nuclear 
fraction was run on the transcription factor assay kit (Abcam, ab133128).  
Transgenic Mice 
The KRas/LKB1-null/Luciferase transgenic mouse is a well-characterized model of LKB1-deficient 
NSCLC (1).   Expression of Cre recombinase in the lung, via intra-tracheal introduction of the 
Cre-adenovirus, results in biallelic deletion of the floxed LKB1 gene,activation of the KRas 
oncogene and expression of Luciferase. Luciferase will bind Luciferin, which can be visualized 
using a Xenogen. Deletion of LKB1 and over activation of KRas results in an aggressive tumor 
burden on the mice, with an average survival time of 9 weeks. Tumor burden is visualized on a 
Xenogen and relative optical intensity measured. 4 weeks post infection, mice were (check tense) 
randomized to vehicle, CCL2 neutralizing antibody at 5mg/ml twice per week (R&D; AB-479-NA) 
or a CCR2 antagonist (Sigma; SML0711-25mg) at 2mg/kg twice per day. Tissues were digested 
using Collagenase IV (Life Tech; 17104-019). 
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CHAPTER 3 
RESULTS 
Molecular Pathway/Mechanism 
 To investigate the effects of LKB1 deficiency on gene 
expression, an mRNA array was performed on the human lung 
adenocarcinoma cell line, H23 (LKB1 -/- ). Functional LKB1 or a 
Kinase Dead LKB1 (KDLKB1) were re-expressed into the H23 
cell line to elucidate the role of LKB1 upon gene expression. 
Notably, CCL2 mRNA expression was 242 fold higher in the 
KDLKB1 compared to LKB1 (Table 1). 
Consistent with these data, quantitative ELISA results 
demonstrated that H23 KDLKB1 cells secreted 7868pg/ml of 
CCL2 compared to 63 
pg/ml in the H23 LKB1 (Figure 1). Conversely, using 
the Lenti-virus CRISPR system, LKB1 was knocked 
down in CMT 64 cells (mouse lung carcinoma, LKB1+/+) 
and CCL2 was increased by 11 fold (Figure 2). Lysates 
were collected and 
blotted for LKB1 to 
ensure knockdown 
(S4). Furthermore, 
other LKB1 null (H838, A549) NSCLC cell lines secreted 
significantly higher CCL2 levels compared to LKB1 expressing 
(H2009, H358, H441) NSCLC cell lines (Table 2). 
Immunohistochemistry was performed on transgenic 
KRAS+/LKB1+ vs. KRAS+/LKB1-  NSCLC mouse tumors using an 
Table 1 Gene expression array on 
H23 Human Lung Adenocarcinoma 
cell line with the LKB1 re-expression 
or Kinase Dead-LKB1 (KDLKB1). 
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Figure 1 Quantitative ELISA on H23 
isogenics, expressed with full length LKB1 
(LKB1 +) or Kinase Dead LKB1 (LKB1 -) 
*p=0.002. 
Figure 2 Quantitative ELISA on CMT 64 
parentals and CMT 64 with CRISPR 
deletion of LKB1 *p=0.03. 
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anti-murine CCL2 antibody. The LKB1 null tumors displayed distinctly higher levels of CCL2 
compared to LKB1 wild type (Figure 3).  
To investigate the mechanistic role of LKB1 deficiency on CCL2 secretion, 
signaling pathways de-regulated with LKB1 deficiency were targeted with 
inhibitory drugs in H23 and H2030 cell lines. mTOR, PI3K,SRC family and 
MEK inhibitors are therapeutic strategies for targeting in LKB1-/-/KRas 
tumors. PI3K and SRC families up-regulate mTOR and MEK is de-regulated 
with oncogenic KRas (14). NF-κB was targeted due to its known 
inflammatory response cascade. 
AMPK ordinarily inhibits the 26s 
proteasome, which serves to degrade 
transcription factors involved in cell 
cycle progression and apoptosis (7). Dasatinib (SRC 
family inhibitor), LY294002 (PI3K Inhibitor),  
U0126 (MEK 
inhibitor) 
resulted in 
minimal reduction of CCL2 secretion. Rapamycin 
(mTOR inhibitor), significantly reduced CCL2 secretion 
in H23 (p = 0.009) cells but only an 8% reduction was 
seen in H2030 cells. However, Bortezomib (26s 
proteosome and NF-κB inhibitor) and BAY-11-7082 
(NFκB inhibitor) substantially reduced CCL2 secretion in 
both cell lines (p=0.002) (Figure 4). Lysates were 
collected from the treatments and blotted for β-actin to 
ensure no change in global protein expression (S1).  
Table 2 Human CCL2 quantitative 
ELISA from LKB1-/- and LKB1 +/+ 
NSCLC cell lines. 
   Cell line  pg/ml CCL2  
LKB1 +  
H2009  34.25, ± 2.75  
H358  39.75, ± 7.75  
H441  98.25, ±5.75  
LKB1-  
H23  12866, ± 492  
H838  3242.5, ± 203  
A549  3256.75, ±479  
Figure 3 A. KRas/LKB1 
wild-type CCL2 IHC staining 
samples from transgenic 
mice. B. KRas/LKB1 null 
sample. 
Figure 4  Quantitative ELISA for CCL2 from media 
collected from H23 and H2030 cells treated with 
vehicle, Dasatinib 250nM, LY294002 10nM, U0126 
10µM, Rapamycin 10nM, Bortezomib 100nM, or 
Bay-11-7082 10µM for 24 hours.  
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Figure 5 Western blots comparing 
H23 LKB1 and H23 KDLKB1. HIF1-α 
is higher in both high and low 
glucose in KDLKB1 compared to 
LKB1. P-AMPK demonstrates a 
decrease of activity in KDLKB1. 
We further investigated the influence of mTOR signaling on 
CCL2 secretion to elucidate potential reasons why rapamycin 
treatment resulted in a drastic decrease in CCL2 in the H23 but 
not H2030. Loss of LKB1 has been shown to increase the 
transcription factor Hypoxia Inducible Factor 1 -alpha (HIF1-α) 
even under normoxic conditions, due to hyper activation of 
mTOR signaling in an animal model of Peutz-Jeghers 
syndrome (13,14). CCL2 expression has been found to be 
regulated by HIF-1α under hypoxic conditions (15). In 
H23KDLKB1 cells, under high and low glucose with normoxic conditions, HIF1-α is markedly 
higher than H23 LKB1 cells (Figure 5). To evaluate 
the role of HIF1-α on CCL2 regulation under normoxic 
conditions, we used 5nM siRNA for HIF1-α in H23 and 
H2030 cell lines and performed a quantitative ELISA. 
CCL2 secretion was reduced by 10% in H23 and 8% 
in H2030 treated with si HIF1-α (Figure 6). These 
findings suggest that while HIF1-α is upregulated with 
LKB1 deficiency, it does not have a critical role in 
CCL2 expression.  
 We then interrogated the role of NF-κB 
signaling on CCL2 secretion. NF-κB signaling 
mediated by IL-1β and TNFα has also been shown to 
regulate CCL2 in rat astrocytes (16). FLIP1 (an-LKB1 
interacting cytoplasmic protein) has been shown to 
negatively regulate TNF-α induced NF-κB activation 
(17). We demonstrated increased NF-κB activity in 
LKB1 null lines (H23,H2030,A549 and H838)  compared to LKB1 wild-type lines (H2009 
andH1975) (p=0.018) (Figure 7). Furthermore, in LKB1 deficient lines A549, H838, H23 and 
Figure 6 A. Western blot for HIF1-α 
demonstrating knockdown. B. Quantitative ELISA 
illustrating pg/ml of CCL2 with 5nM si HIF1-α. 
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H2030 cells treated with the NF-κB inhibitor, 
Bay 11-7082 5µM, CCL2 secretion was 
reduced by an average 91% with minimal 
effects on cell viability (Figure 8).  
Function 
  CCL2 is an inflammatory chemokine 
known to recruit monocytes to infected or 
injured tissue.  To test the chemotaxic 
effects of LKB1 deficiency, conditioned H23 
media was utilized in a chemotaxis assay 
using human peripheral blood mononuclear 
cells (PBMCs). Monocytes preferentially 
migrated toward H23 conditioned media 
(8.2% of the total PBMC population was 
CD11c+ and CD14+ (monocyte markers), 
but only 1.7% for H2009 conditioned 
media (Figure 9). The necessity of the 
CCL2/CCR2 signaling axis on monocyte 
recruitment in H23 conditioned media 
was evaluated using a neutralizing CCL2 
antibody, CCR2 or CCR4 antagonist with 
peripheral blood mononuclear cells in a 
migration assay. All treatments reduced 
monocyte migration toward H23 conditioned media as evaluated by flow cytometry (Figure 10).  
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Figure 7 NF-κB activity ELISA demonstrates significantly 
higher activity in LKB1-/- cell lines compared to LKB1 wild-
type (p=0.014).  
Figure 8 Quatitative ELISA for CCL2 from media 
collected from A549, H838, H23, H2030 cells treated with 
5µM Bay 11-7082 for 4 hours. Viability assessed by cell 
titer glo (Promega G9241) luminescence kit measuring 
ATP levels. 
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In vivo  
To assess the effects of CCL2/CCR2 
signaling in LKB1- NSCLC in vivo we 
infected KRas/LKB1/Luciferase mice 
with Cre recombinase adenovirus via 
intra-tracheal injections. To mimic 
patient staging at diagnosis, mice were 
imaged six weeks post infection, using 
a Xenogen to assess tumor burden. 
Mice were then randomized to 
treatment groups of: Vehicle (PBS), 
Figure 9 Flow cytometric analysis of peripheral blood mononuclear 
cell migration towards conditioned media. 17.14% of migrated cells 
stained with CD14 and CD 11c were double positive (monocytes) 
with H23 conditioned media and 2.48% were double positive with 
H2009 conditioned media.  
Figure 10 Flow cytometry analysis of PBMC migration toward H23 conditioned media +/- CCL2 (50ng/ml), CCR2 
(20nM), and CCR4 (300nM). Percentage indicates CD14+ and CD11c+ positive cells out of the total collected 
population of PBMCs.  
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CCL2 neutralizing antibody at 5mg/ml twice per week (R&D; AB-479-NA) or a CCR2 antagonist 
(Sigma; SML0711-25mg) at 2mg/kg twice per day for a total of four weeks. Whole lung samples 
were digested at 10 weeks and analyzed via flow cytometry. Cells were stained with CD206, 
F4/80, Cd11b and GR-1. Although our sample size (3n) makes it difficult to definitively determine 
if inhibition of the CCL2-CCR2 signaling axis has 
effects upon LKB1- NSCLC progression, we did 
not see significant change in tumor progress via 
Xenogen imaging (Figure 11). However, 
reductions in the M2 (Cd11b+, F4/80+, 
CD206+):M1 (Cd11b+, F4/80+,CD206-) ratio was 
observed (Figure 12). Although there are distinct 
functions between N1 and N2 neutrophils, no 
definitive receptor markers differentiating the 
population have been identified. Therefore, TAN 
infiltrate was evaluated by measuring mature 
neutrophil (Cd11b+, Ly6G+) percentages to total 
lung population (Figure 13). Treatment with CCR2 antagonist reduced the M2:M1 ratio by an 
Figure 11 Transgenic LKB1/KRas/Luciferase mouse at 6 weeks, 8 weeks and 10 weeks post infection with 
Cre recombinase adenovirus via intra-tracheal injections. Treatment with CCR2 antagonist via oral gavage 
began at 6 weeks. See supplemental data for other treatment groups.
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Figure 12 The ratio of M2 (Cd11b+, F4/80+, 
CD206+): M1(Cd11b+, F4/80+,CD206-) 
macrophages analyzed by flow cytometry. In mice 
treated with a CCR2 antagonist or α-CCL2, a 
significant reduction (p=0.004 and 0.04, respectively) 
was seen in the M2:M1 ratio.  
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average 2.8 fold and reduced the TAN infiltrate by an average 1.2 fold. Treatment with anti-CCL2 
reduced the M2:M1 ratio by 1.8 fold and 
had no significant effect on TAN 
infiltrate. An early stage study was also 
performed to evaluate the effects on 
early tumor progression. Mice were 
infected with Cre recombinase 
adenovirus via intra-tracheal injections 
then immediately randomized to 
treatment groups of: Vehicle (PBS), 
CCL2 neutralizing antibody at 5mg/kg 
twice per week or a CCR2 antagonist 
at 2mg/kg twice per day for a total of four weeks. No significant reduction in tumor progression 
was observed via Xenogen imaging after 4 weeks (data not shown), however, M2:M1 ratio and 
TAN infiltrate were reduced (S2 and S3).  
 
Beyond CCL2  
While CCL2 was the primary focus of 
this project, other cytokines and factors 
may also play a role in the alteration of 
the immune microenvironment. Based 
on our preliminary mRNA array we ran 
quantitative ELISAs for CCL5 and 
CCL20 in LKB1 wt and LKB1 null cell 
lines. LKB1 null lines secreted 
substantially higher of CCL5 and/or CCL20 compared to LKB1 wt (Table 3). A cytokine array was 
performed on H23 to assess potential factors leading to TAM and TAN polarization and tumor 
environment remodeling (Figure 14). Serpin E1 was 223 fold higher in KDLKB1 compared to 
 Cell line pg/ml CCL5 pg/ml CCL20 
LKB1 
+ 
H2009 29.14 +/- 0.13 37.1 +/- 0.05 
H358 0.36 +/- 0.01 0 +/- 0.01 
H441 32.75 +/- 0.06 2.30 +/- 0.05 
LKB1- 
H23 267.89 +/- 0.04 1221.78 +/- 0.05 
H838 58.71 +/- 0.02 29.06 +/- 0.05 
A549 104.56 +/- 0.05 2.83 +/- 0.07 
A427 8.29 +/- 0.04 6254 +/- 0.04 
H2030 0.083 +/- 0.01 81.2 +/- 0.07 
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Table 3 Quantitative ELISA for CCL5 and CCl20 from 
LKB1 -/- and LKB1 +/+ NSCLC cell lines.  
Figure 13 TAN infiltrate analyzed by flow cytometry. TAN 
(Cd11b+,Gr-1+) percentages assessed over total lung 
population.  
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LKB1 wt (S4). Serpin E1 is a serine 
protease inhibitor that has been 
shown to be a biomarker for poor 
prognosis in various cancers. Serpin 
E1 promotes tumor progression 
likely by modulating matrix 
remodeling (18). I-309 (or CCL-1) is 
secreted by activated T-cells and 
also recruits monocytes. G-CSF, 
colony-stimulating factor, is 
a glycoprotein that stimulates 
the bone marrow to produce granulocytes. The inter-leukin family can have a wide effect on the 
immune cell population and activation.  
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Figure 14 Cytokine Array in H23 cell indicating fold change in 
substrates with higher mean pixel density from kinase dead 
LKB1 to full length LKB1.  
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CHAPTER 4 
DISCUSSION 
Data Summary 
We demonstrate that with deletion of LKB1, non-small cell lung cancer cells upregulate the 
chemokine, CCL2. Quantitative ELISA on H23, A549 and H838 NSCLC LKB1 deficient lines 
demonstrates significantly higher secretion of CCL2 than H2009, H358, and H441 NSCLC LKB1 
wild-type lines. Full length LKB1 or Kinase Dead LKB1 was expressed in H23 cell lines; LKB1 
expression in H23 cells considerably reduced CCL2 secretion. The reverse effect was observed 
in CMT64 with LKB1 knocked-down using the CRISPR system. With LKB1 deletion, CCL2 
secretion is substantially increased compared to parental, LKB1 wild-type CMT 64 cells. This 
phenotype is also seen in transgenic KRas/LKB1 mice via immunohistochemistry for CCL2. Thus, 
we reveal that loss of LKB1 is correlated with up-regulation of CCL2.  Inhibition of the 
CCL2/CCR2 signaling axis via anti-CCL2 antibody or a CCR2 antagonist significantly reduced 
monocyte migration from peripheral blood mononuclear cells in vitro. The molecular mechanism 
governing the increased expression needs to be further evaluated, however, we reveal a potential 
role for NF-κB mediated alteration of the immune microenvironment. Inhibition of NF-κB with the 
inhibitor, Bay 11-7082, substantially reduced CCL2 secretion in H23, H2030 and A549 cells. Our 
in vivo data demonstrate that treatment with a CCR2 antagonist reduces the M2:M1 ratio and 
TAN infiltrate in our transgenic LKB1/KRas/Luciferase mice.  Anti-CCL2 and CCR2 antagonist 
treatment in the early stage group revealed a similar pattern in M2:M1 and TAN infiltrate 
reduction, however, a larger sample size is necessary to assess significance, as well as to 
ascertain what these changes have upon NSCLC progression. Loss of the LKB1 pathway causes 
up-regulation of the transcription factor, NF-κB which causes the expression of CCL2 and other 
chemokines, such as CCL5 and CCL20. These chemokines recruit monocytes and neutrophils to 
the tumor microenvironment where differentiation into M2 macrophages and TANs occurs. M2 
macrophages and TANs have been shown to be correlated with poor prognosis in and increased 
tumor progression in many cancers, however, further research needs to be done to evaluate the 
16 
effects of M2 and TAN infiltrate in LKB1 deficient NSCLC (2). Taken together, these data indicate 
that loss of LKB1 in NSCLC leads to alterations of the immune cell environment within the tumor. 
Significance and Therapeutic Opportunities 
 Despite aggressive therapy, non-small cell lung cancer (NSCLC) continues to be the 
primary contributor to cancer related deaths. Most patients present with distant metastases and 
often relapse after chemo-radiation. LKB1 is frequently mutated in conjunction with KRas in 
NSCLC yet little to no targeted therapeutics options are available. We sought to characterize the 
aggressive phenotype seen with LKB1 deletion and elucidate the role of the immune system in 
cancer progression. M2 macrophages enhance cancer progression by secreting proliferative 
factors (FGF), extra-cellular matrix remodeling enzymes (MMPs), metastatic capabilities (VEGF, 
Angiogenin) and adaptive immunity evasion (IL-10 and CCL17). N2 neutrophils further aid the 
progression by increasing proliferation (PDGFR signaling), extra-cellular matrix remodeling 
(MMPs), angiogenesis (Gro-α), cancer cell migration (HGF secretion), and immune cell evasion 
(CXCL9). Other studies suggest N2 neutrophils play a role in tumor initiation by reactive oxygen 
species mechanisms (13). We demonstrate the significance of the CCL2/CCR2 signaling axis in 
TAM and TAN infiltration. Antibodies against CCL2 and CCR2 have been investigated in pre-
clinical trials in prostate cancer, breast cancer, ovarian cancer and have shown improved survival 
and reduced metastases (23). Trabectedin, derived from Ecteinascidia turbinate, is preferentially 
cytotoxic for both human and murine TAMs and inhibits production of CCL2 and IL-6 (24). 
Reparixin, a potent inhibitor of CXCR1 and CXCR2 has been demonstrated to selectively target 
human breast cancer cells and inhibit the recruitment and activation of neutrophils (25). The NF-
κB pathway also shows promise for cancer therapy; bortezomib leads to lung tumor regression 
and increased survival KRas/P53-/- mice (26). 
Future Studies 
Further evaluation of the mechanism governing an inflammatory response and alteration of the 
immune system is critical to generating target therapeutics for LKB1 deficient NSCLC patients. 
While we show a correlation between NF-κB and CCL2, the exact mechanism governing the 
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increased CCL2 expression with LKB1 loss need to be further examined. Bay-11-7082 is an 
inhibitor of NF-κB by selectively and irreversibly blocking TNF-α-induced phosphorylation of IκB-
α. IkB-α binds to NF-κB and keeps it in the inactive form in the cytoplasm until phosphorylation of 
IκB causes release of NF-κB. However, to gain an accurate understanding of the function of NF-
κB in regards to CCL2 secretion and LKB1 loss, NF-κB needs to be evaluated beyond the scope 
of a single drug. A dominant negative NF-κB or siNF-κB introduction could also be used in H23, 
H2030, H838 and A549 cells and CCL2 secretion evaluated. The pathway leading to the up-
regulation of NF-κB should also be investigated. Discovering an upstream target of NF-κB may be 
a beneficial targeted therapeutic option for patients. However, an NF-κB inhibitor could be used in 
our transgenic KRas/LKB1/Luciferase model to evaluate the effects on tumor progression and 
pro-tumor immune cell infiltrate. Investigation of what factors are necessary for M2 and N2 
polarization could provide a preventative avenue. Although we demonstrate an ability to reduce 
pro-tumor immune cell populations, blockading chemotaxic factors also reduces anti-tumor 
immune cell populations. Further investigation should be done to explore causative factors in anti-
tumor immune cell differentiation such that pro-tumor cells can still function to reduce tumor 
growth. Studies have shown several factors cause M2 and N2 activation, but further exploration 
in an LKB1 deficient context could provide a better understanding of pro-tumor immune cell 
activation. Our in vivo study should be expanded to a larger treatment group, a longer time 
course allowed to evaluate metastases and CCR2/CCL2 treatment compared to combination 
therapy. The CCR2 antagonist could be combined with other receptor antagonists (such as 
CCR4) in addition to combination with cytotoxic drugs that would aid in reducing tumor 
proliferation and progression. Further analysis of the importance of CCL2/CCR2 signaling in the 
metastatic process is critical. CMT 64 CRISPR LKB1 knockdown cells could be injected into the 
flank of a CCR2 knockout mouse and metastatic seeding compared to CMT 64 empty vector 
flank injections.  
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CHAPTER 5 
SUPPLEMENTAL DATA 
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S1 Lysates from H23 and H2030 cell lines after 
indicated treatment were collected and blotted 
for β-actin.
S2 The ratio of M2 (Cd11b+, F4/80+, CD206+): M1(Cd11b+, F4/80+,CD206-) 
macrophages analyzed by flow cytometry  in mice treated with a CCR2 
antagonist or α-CCL2 a for 4 weeks post infection, a reduction is seen in the 
M2:M1 ratio. 
S3 TAN infiltrate analyzed by flow cytometry. TAN (Cd11b+,Gr-1+) percentages 
assessed over total lung population.
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